Wave Life Sciences ​shares plunged 58% on Thursday after a higher dose of its experimental obesity ‌drug failed to show a clear improvement at reducing a dangerous type of belly fat.

On March 26, 2026, traders mulled Wave's weak high-dose obesity results against the company's large market opportunity.

Wave Life Sciences (WVE) stock plunges as the company interim data from an early-stage trial for WVE-007, its RNA-based obesity medicine. Read more here.

Achieve exceeded long-term safety study requirements and secured a manufacturing partnership, positioning for a potential 1H 2027 commercial launch if approved. Read the full analysis here.

Anavex shares crash as the EMA indicates it won’t issue a positive opinion on its candidate Alzheimer’s drug. Here’s why long-term investors may still consider loading up on AVXL stock today.

Wave Life Sciences (NASDAQ:WVE) saw its shares fall more than 52% following the release of six-month Phase 1 data for WVE-007 ...

Texas A&M AgriLife renamed its Poultry Science Farm Complex to honor donor support of the poultry science program and its ...

The American Association for the Advancement of Science, AAAS, bestowed the title of AAAS Fellow upon Bradford Wilcox, Ph.D., ...

ELMED Life Sciences secures $2.7 million in Series A funding from AgriSure Fund to enhance growth and expand operations.

Wave Life Sciences stock crashed Thursday after the company's much-hyped "body composition" drug led to just 1% weight loss in six months.

The OpenAI Foundation, under OpenAI chair Bret Taylor, embarks on an ambitious $1 billion plan for A.I. safety, health and ...

Wave Life Sciences Ltd. (NASDAQ:WVE) shares fell 30% Thursday following the company’s announcement of interim Phase 1 data from its INLIGHT trial evaluating WVE ...